Skip to main
SPTX

SPTX Stock Forecast & Price Target

SPTX Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Seaport Therapeutics is a promising clinical-stage therapeutics company with a strong management team and valuable assets in the Glyph2BLSD program. Their focus on validated mechanisms and innovative drug delivery technology gives them a competitive edge in the market, but as a young company, there are risks and uncertainties to consider. The ongoing clinical trials for their lead assets, GlyphAllo and GlyphAgo, will be crucial in determining the success and future growth of the company.

Bears say

Seaport Therapeutics is a clinical-stage therapeutics company focused on developing new medicines for patients with depression and anxiety, but its stock faces risks due to potential competition and litigation around its patented lymphatic-targeting prodrug technology, Glyph. While the company has shown promising results in initial studies with its lead assets, GlyphAllo and GlyphAgo, there are risks associated with the limited operating history of the company and the highly litigious nature of the pharmaceutical industry. Additionally, the brexanolone and zuranolone compounds, which work on a similar receptor as Glyph, were not successful in clinical trials and may suggest potential issues for Seaport's compounds as well. However, Seaport's CEO Daphne Zohar has a successful track record in the industry, and the company is conducting ongoing efforts to safeguard and strengthen its patent position.

SPTX has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Seaport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Seaport Therapeutics Inc (SPTX) Forecast

Analysts have given SPTX a Strong Buy based on their latest research and market trends.

According to 6 analysts, SPTX has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Seaport Therapeutics Inc (SPTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.